Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in France.

Maxime DougadosJulien LucasEmilie DesfleursCédric LukasAlain SarauxAnne TournadreAdeline Ruyssen-WitrandDaniel WendlingPhilippe GoupillePascal Claudepierre

Published in: RMD open (2022)

This study suggests that reporting of recommended composites indices for monitoring axSpA might be associated with higher retention rates of biological therapies.

Keyphrases

disease activity
ankylosing spondylitis
rheumatoid arthritis
systemic lupus erythematosus
rheumatoid arthritis patients
healthcare
juvenile idiopathic arthritis
adverse drug
primary care
physical activity
combination therapy
reduced graphene oxide